Blood Morphology Automation Expands with Scopio Labs Securing Additional $10 Million Funding
Scopio Labs, a leading innovator in the field of hematology diagnostics, has launched a groundbreaking AI-based Complete Blood Morphology (CBM) analyzer. This new technology is poised to significantly transform the hematology market and enhance laboratory efficiency[1][2][4].
While Complete Blood Counts (CBCs) are automated, the review of Peripheral Blood Smears (PBSs) typically requires human intervention. Scopio's CBM analyzer automates this traditionally manual blood morphology diagnostic process, offering a more standardized, scalable, and rapid morphology review process[1].
The CBM analyzer is designed to analyze peripheral blood smears and examine 10 times more cells than traditional methods. This automation, enabled by computational imaging and AI, promises a more accurate and consistent morphology review process, reducing variability and human error[1].
Key impacts of the CBM analyzer include increased throughput and scalability, improved standardization, enhanced diagnostic depth and speed, and market disruption[1][2][4]. By autonomously detecting, classifying, and quantifying thousands of blood cells downstream of existing CBC analyzers, CBM can boost lab throughput and reduce the hands-on time required for manual slide review[1][2].
The CBM system represents a "major leap forward" in hematology diagnostics and could challenge conventional approaches by offering a fully AI-powered, digital solution that integrates seamlessly with existing workflows[1][4]. Analyzing a much larger cell population enables deeper insights into blood morphology, potentially improving diagnostic accuracy and patient care timelines[1][5].
Although the CBM analyzer is still under development and not yet available for in vitro diagnostic use, it has received CE and FDA clearances for related digital imaging platforms, signaling regulatory confidence in its technology[1][5]. Its adoption could encourage broader lab automation trends highlighted by competitors offering comprehensive hematology solutions aimed at increasing productivity and standardization[3].
Investment firm Viola Growth has shown confidence in Scopio's innovative technology, investing an additional $10 million, raising Scopio's Series D funding to $52 million[6]. Viola Growth is excited to join Scopio on their journey to reshape the future of hematology diagnostics[6]. Scopio Labs' CEO, Itai Hayut, continues to believe that the CBM will transform the hematology market[7].
The CBM analyzer will be showcased at the ADLM 2025 Annual Conference, providing an opportunity for industry professionals to witness this revolutionary technology firsthand[8]. With its potential to eliminate the need for routine human reviews in the hematology market, deliver fully automated results, and provide autonomous morphology review with the depth, speed, and scalability that the critical step urgently needs[1], Scopio Labs' CBM analyzer may lead to faster, more accurate, and scalable hematology testing, improving laboratory efficiency and enhancing the overall hematology diagnostics market through advanced AI automation[1][2][4].
[1] Scopio Labs. (n.d.). Scopio Labs' CBM Analyzer. Retrieved from https://scopio.ai/products/cbm/ [2] Scopio Labs. (n.d.). Scopio Labs' CBM Analyzer: Autonomous Morphology Review. Retrieved from https://scopio.ai/products/cbm/ [3] Scopio Labs. (n.d.). Scopio Labs' CBM Analyzer: The Future of Hematology Diagnostics. Retrieved from https://scopio.ai/products/cbm/ [4] Scopio Labs. (n.d.). Scopio Labs' CBM Analyzer: Market Disruption. Retrieved from https://scopio.ai/products/cbm/ [5] Scopio Labs. (n.d.). Scopio Labs' CBM Analyzer: Regulatory Clearances. Retrieved from https://scopio.ai/products/cbm/ [6] Scopio Labs. (n.d.). Viola Growth Invests $10 Million in Scopio Labs. Retrieved from https://scopio.ai/news/viola-growth-invests-10-million-in-scopio-labs/ [7] Scopio Labs. (n.d.). Scopio Labs' CEO, Itai Hayut, on the CBM Analyzer. Retrieved from https://scopio.ai/news/scopio-labs-ceo-itai-hayut-on-the-cbm-analyzer/ [8] ADLM. (n.d.). ADLM 2025 Annual Conference. Retrieved from https://adlm.org/annual-conference/
The CBM analyzer, a groundbreaking AI-based technology, automates the traditionally manual blood morphology diagnostic process, offering a more standardized, scalable, and rapid morphology review process in the field of hematology diagnostics. With the ability to analyze peripheral blood smears and examine 10 times more cells than traditional methods, this technology is poised to significantly transform the hematology market, leveraging technology to improve healthcare and medical-conditions through health-and-wellness diagnostics.
